Discover. Oncology最新文献

{"title":"Influence of the lncRNA SLC9A3-AS1 on colon cancer and the biological activities of colon cancer cells.","authors":"Xiulian Xu, Hongyi Qing, Chunyan Jiang, Xiaofeng Zhao, Jinlai Wei","doi":"10.1007/s12672-025-02134-w","DOIUrl":"10.1007/s12672-025-02134-w","url":null,"abstract":"<p><strong>Background: </strong>Circulating long non-coding RNAs expression was associated with diagnosis and therapies of various diseases. The current study investigated the expression of lncRNA SLC9A3-AS1 in the serum samples from colon cancer patients and explored its potential functions in colon cancer cells.</p><p><strong>Methods: </strong>Serum expression levels of SLC9A3-AS1 and miR-486 were measured in 130 patients with colon cancer and 96 healthy individuals using RT-qPCR. The influence of SLC9A3-AS1 expression and miR-486 expression on colon cancer cellular behaviors was detected by MTT assay and Transwell chamber assays. Pearson correlation analysis was used to analyze the association between SLC9A3-AS1 and miR-486.</p><p><strong>Results: </strong>We found serum expression levels of SLC9A3-AS1 were overexpressed in sera of colon cancer patients. ROC curve analysis showed that SLC9A3-AS1 had a high area under the ROC curve value for early detection of colon cancer patients from a healthy control. The proliferation potential, migration, and invasion behaviors were weakened by si-SLC9A3-AS1 and reversed by the miR-486 inhibitor.</p><p><strong>Conclusion: </strong>Serum SLC9A3-AS1 may be used as a non-invasive diagnostic predictor for the early screening of colon cancer. LncRNA SLC9A3-AS1 affects colon cancer cellular activities by negatively modulating miR-486. A major limitation of this study is the small sample size, and in addition, the lack of longitudinal data prevented us from conducting an in-depth analysis of long-term changes in variables.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"358"},"PeriodicalIF":2.8,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression profiles of FABP4 and FABP5 in breast cancer: clinical implications and perspectives.","authors":"Xingshan Jiang, Yiqin Xiong, Jianyu Yu, Anthony Avellino, Shanshan Liu, Xiaochun Han, Zhaohua Wang, Jonathan S Shilyansky, Melissa A Curry, Jiaqing Hao, Edward R Sauter, Yi Huang, Sonia L Sugg, Bing Li","doi":"10.1007/s12672-025-02117-x","DOIUrl":"10.1007/s12672-025-02117-x","url":null,"abstract":"<p><p>The incidence of breast cancer continues to rise each year despite significant advances in diagnosis and treatment. Obesity-associated dysregulated lipid metabolism is believed to contribute to the increasing risk of breast cancer. However, the mechanisms linking lipid dysregulation to breast cancer risk and progression remain to be determined. The family of fatty acid binding proteins (FABPs) evolves to facilitate lipid transport and metabolism. As the predominant isoforms of FABP members expressed in breast tissue, adipose FABP (A-FABP, also known as FABP4) and epithelial FABP (E-FABP, FABP5) have been shown to play critical roles in breast carcinogenesis. In this study, we collected surgical breast tissue samples from 96 women with different subtypes of breast cancer and comprehensively analyzed the expression pattens of FABP4 and FABP5. We found that distinct expression profiles of FABP4 and FABP5 were associated with their unique roles in breast cancer development. FABP4, mainly expressed in breast stroma, especially in adipose tissue, likely supported neighboring tumor cell lymphovascular invasion through secretion from adipocytes. In contrast, FABP5, primarily expressed in epithelial-derived tumor cells, could promote tumor metastasis by enhancing lipid metabolism. Thus, elevated levels of FABP4 and FABP5 may serve as poor prognostic markers for breast cancer. Inhibiting the activity of FABP4 and/or FABP5 may offer a novel strategy for breast cancer therapy.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"357"},"PeriodicalIF":2.8,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding male breast cancer: epidemiological insights, cutting-edge treatments, and future perspectives.","authors":"Lei Zhao, Huijuan Cheng, Dongqiang He, Yalan Zhang, Yahui Chai, Ailin Song, Guodong Sun","doi":"10.1007/s12672-025-02140-y","DOIUrl":"10.1007/s12672-025-02140-y","url":null,"abstract":"<p><p>Breast cancer is predominantly recognized as a condition affecting women, however, male breast cancer (MBC), despite its rarity, represents a significant and serious malignancy in men. Accounting for approximately 1% of all breast cancer cases, MBC is often diagnosed at a later stage compared to female breast cancer, primarily due to a lack of awareness and the absence of screening programs tailored for men. This delayed diagnosis typically results in poorer prognoses and more limited treatment options. Over the past decade, there has been a notable increase in research and awareness surrounding MBC. This surge is largely driven by the recognition of its unique epidemiological and biological characteristics, which are distinct from those of female breast cancer. However, due to its low incidence, many aspects of MBC, including its etiology, clinical presentation, and optimal treatment strategies, remain inadequately understood. This paper aims to provide a comprehensive review of MBC by examining its incidence, mortality rates, and epidemiological characteristics on a global scale. Additionally, it explores the economic burden associated with the disease, identifies key risk factors, and discusses current preventive measures. Finally, the paper will offer insights into future research directions and potential advancements in the diagnosis and treatment of MBC.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"360"},"PeriodicalIF":2.8,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional relationship between platelet count and skin cancer: tumor drug resistance mechanisms.","authors":"Chao Guo, Jiaqin Deng, Tianhua Wen, Jinzhou Li, Peilin Zeng, Chao Liang","doi":"10.1007/s12672-025-02122-0","DOIUrl":"10.1007/s12672-025-02122-0","url":null,"abstract":"<p><strong>Background: </strong>Platelets (PLT) play a crucial role in tumor progression, including tumor growth, metastasis, and immune evasion. However, the relationship between PLT count and specific skin cancer subtypes, particularly melanoma skin cancer (MSC) and non-melanoma skin cancer (NMSC), remains poorly understood. Clarifying this association could identify potential biomarkers and therapeutic targets for personalized treatments.</p><p><strong>Methods: </strong>We applied bidirectional Mendelian randomization (MR) to investigate the causal relationship between PLT count and skin cancer risk, focusing on MSC and NMSC. Genetic variants associated with PLT and skin cancer served as instrumental variables for causal inference. Nine MR analysis methods, with inverse-variance weighted (IVW) as the primary method, were used to assess robustness, heterogeneity, and pleiotropy.</p><p><strong>Results: </strong>Forward MR analysis showed no significant relationship between PLT count and overall skin cancer or NMSC. However, elevated PLT was linked to an 18.6% increased risk of MSC. Reverse MR analysis revealed that skin cancer, particularly NMSC, negatively affected PLT count, while MSC was associated with a positive influence on PLT levels. No significant heterogeneity or pleiotropy was detected.</p><p><strong>Conclusions: </strong>Our findings reveal a bidirectional, subtype-specific relationship between PLT and skin cancer. Elevated PLT levels specifically increase the risk of MSC, while MSC influences PLT count positively. In contrast, NMSC is associated with lower PLT levels. These results suggest that PLT could serve as both a prognostic marker and a potential therapeutic target, particularly for MSC. Further research is needed to explore the molecular mechanisms underlying these associations and to investigate the role of PLT in overcoming tumor resistance to therapies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"361"},"PeriodicalIF":2.8,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of fructose-1,6-bisphosphatase 1 on regulating the cancer progression and drug resistance.","authors":"Mengmeng Wang, Xiaoju Huang, Dan Zhang, Yisan Liu, Pian Liu","doi":"10.1007/s12672-025-02112-2","DOIUrl":"10.1007/s12672-025-02112-2","url":null,"abstract":"<p><p>Fructose-1,6-bisphosphatase 1 (FBP1) is the enzyme that limits the process of gluconeogenesis as it facilitates the hydrolysis of fructose-1,6-bisphosphate(F-1,6-BP) to produce fructose-6-phosphate(F6P) and inorganic phosphate. Gluconeogenesis is the production of glucose from small carbohydrate substrates. The gluconeogenic process is typically suppressed in cancer because it inhibits glycolysis. Apart from its involvement in cellular glucose metabolism, FBP1 also plays a role in gene transcription, mRNA translation and stability regulation, and the immune microenvironment of tumors. Because of its multifaceted functions, the mechanisms by which FBP1 is involved in tumor development are complex. Moreover, FBP1 deficiency is associated with radiation and chemotherapy resistance and poor prognosis in cancer patients. Restoration of FBP1 expression in cancer cells is expected to hold promise for cancer therapy. However, up to now few reviews have systematically summarized the important functional mechanisms of FBP1 in tumorigenesis and the small molecule compounds that restore FBP1 expression. Therefore, this article addresses the question \"How does FBP1 contribute to cancer progression, and can targeting FBP1 be a potential therapeutic approach?\" by summarizing the effects of FBP1 on cancer development and progression as well as its mediated drug resistance and the future clinical applications of potential small molecule modulators targeting FBP1.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"346"},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the role of PRKCI and key-cancer related genes in breast cancer development and metastasis.","authors":"Hania Shah, Khushbukhat Khan, Yasmin Badshah, Janeen H Trembley, Naeem Mahmood Ashraf, Maria Shabbir, Tayyaba Afsar, Dara Aldisi, Dilawer Khan, Suhail Razak","doi":"10.1007/s12672-025-02133-x","DOIUrl":"10.1007/s12672-025-02133-x","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is one of the most common causes of fatalities in females globally. Rising cases of drug resistance against existing chemotherapeutics are great problem. To address this issue, there is a need to find appropriate biomarker that could be used to detect cancer at early stages, so drug resistance development can be avoided. Protein Kinase C iota (PKCɩ), an AGC kinase, has an oncogenic role in cancers and its expression and Single nucleotide polymorphisms (SNPs) have been reported to be associated with the cancer development. So, the study aims were to examine the expression of PKCɩ, Protein Kinase B (AKT), Suppressor of cytokine signaling 3 (SOCS3), Vascular endothelial growth factor (VEGF), Krupple like factor 3 (KLF3), Tumor protein D52 (TPD52), Hypoxia inducible factor (HIF1α) and microRNA-124 (miR-124) in breast cancer and association of PKCɩ variants (G34W & F66Y) with breast cancer.</p><p><strong>Methods: </strong>Genetic expression assay was performed through real time Polymerase Chain reaction (PCR), whereas the genotypic association of PKCɩ SNPs with breast cancer was accomplished through Tetra-ARMS PCR.</p><p><strong>Results: </strong>The expression levels of PKCɩ, AKT, SOC3, VEGF, HIF1α and TPD52 were elevated in patients as compared to control whereas the expression levels of miR-124 and KLF3 were lowered in patients. Positive association of variant G34W (TT) of PKCɩ with breast cancer has been explored through ARM's PCR, while no association of variant F66Y with breast cancer was found.</p><p><strong>Conclusion: </strong>Hence, the results suggest that PKCɩ and related genes can have a role in breast cancer and after further verification can serve as the potential biomarkers for the early-diagnosis and prognosis of breast cancer.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"350"},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of M2 macrophage-related genes in a prognostic model of lung adenocarcinoma based on bulk RNA and ScRNA datasets.","authors":"Bolin Wang, Xiaofeng Zhou, Di Wu, Lu Gao, Zhihua Wan, Ruifeng Wu","doi":"10.1007/s12672-025-02123-z","DOIUrl":"10.1007/s12672-025-02123-z","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the correlation between M2 macrophages activity with the prognosis of lung adenocarcinoma (LUAD). We sought to identify key genes associated with M2 macrophage activity and examine their relationship with clinicopathological features to elucidate the underlying mechanism.</p><p><strong>Methods: </strong>Published datases were analyzed for differentially expressed genes. After quality control, batch effect removal, and annotation, the scRNA dataset identified M2 macrophage-associated differentially expressed genes in the LUAD group, which were cross-analyzed and referred to as M2 macrophage-linked genes. A risk model was generated using machine learing for these genes. Thereafter, two bulk RNA-seq datasets were used to evaluate the model. We computed risk scores for all samples and grouped them into low and high risk, aiding in the comparison of clinical characteristics, immune and stromal infiltration, and drug sensitivity. Finally, key genes were validated through immunohistochemistry in IPA samples.</p><p><strong>Results: </strong>We identified four key M2 macrophage-linked genes: TIMP1, CAV2, MIF, and SELENBP1. Survival durations in the high-riskscore cluster were lower across the TCGA-LUAD (P = 1.2 × 10^-4), GSE14814 (P = 0.02), and GSE37745 (P = 0.01) data sets. The stromal score, fibroblast infiltration, and cytokinesis activation were increased in the high-risk subgroup. Neutrophil and endothelial cell infiltration and activation of the linolenic acid pathway occurred in the low-risk group. IHC confirmed that CAV2 and SELENBP1 expression was significantly reduced, while TIMP1 and MIF were significantly increased in LUAD, which was consistent with the bioinformatics findings.</p><p><strong>Conclusion: </strong>The role of M2 macrophages in tumor progression could anticipate the prognosis of LUAD and develop novel immunotherapy strategies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"352"},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ki-67 expression in anti-programmed cell death protein-1 antibody-bound CD8⁺ T cells as a predictor of clinical benefit.","authors":"Toshiaki Tsurui, Masahiro Hosonuma, Aya Sasaki, Yuuki Maruyama, Yasunobu Amari, Eiji Funayama, Kohei Tajima, Hitoshi Toyoda, Junya Isobe, Yoshitaka Yamazaki, Yuta Baba, Midori Shida, Yuko Udaka, Emiko Mura, Risako Suzuki, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi, Yutaro Kubota, Atsushi Horiike, Satoshi Wada, Atsuo Kuramasu, Mayumi Tsuji, Yuji Kiuchi, Takuya Tsunoda, Kiyoshi Yoshimura","doi":"10.1007/s12672-025-02060-x","DOIUrl":"10.1007/s12672-025-02060-x","url":null,"abstract":"<p><strong>Aims: </strong>Developing predictive biomarkers for immune checkpoint inhibitors (ICIs) is important. Programmed cell death protein-1 (PD-1) receptor occupancy by anti-PD-1 antibodies on circulating T cells varies among patients. However, the association between the exhaustion of these antibody-bound T cells and the clinical efficacy of ICIs remains unknown. Therefore, the present study was aimed at evaluating this association.</p><p><strong>Methods: </strong>This prospective cohort study included patients with advanced non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC) who received pembrolizumab therapy. Peripheral blood samples were collected during the second cycle of chemotherapy. We analyzed the relationship between exhaustion markers in pembrolizumab-bound (PB) T cells and clinical response.</p><p><strong>Results: </strong>A total of 21 patients were analyzed, including 12 patients with NSCLC and 9 patients with ESCC. The expression of Ki-67 in PB-CD8⁺ T_CM and T_EM was negatively correlated with both clinical response and overall survival.</p><p><strong>Conclusion: </strong>The expression of Ki-67 of PB-CD8⁺ T_CM and T_EM can serve as a predictive biomarker for the clinical benefit of pembrolizumab therapy. Our study suggests that analyzing antibody-bound T cells could be a novel approach to predict the clinical outcomes of PD-1 blockade therapy.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"348"},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pan-cancer analysis of the prognosis and immune infiltration of NSUN7 and its potential function in renal clear cell carcinoma.","authors":"Jinwei Cui, Shiye Ruan, Zhongyan Zhang, Hailiang Wang, Qian Yan, Yubin Chen, Jiayu Yang, Jike Fang, Qianlong Wu, Sheng Chen, Shanzhou Huang, Chuanzhao Zhang, Baohua Hou","doi":"10.1007/s12672-025-02061-w","DOIUrl":"10.1007/s12672-025-02061-w","url":null,"abstract":"<p><strong>Background: </strong>NSUN7, an enzyme responsible for the RNA m5c modification, has been recognized as a valuable indicator for predicting and diagnosing an array of cancer. Nevertheless, there is still a scarcity of thorough analyses exploring its diagnostic, predictive, and immune system-related importance in various types of cancer.</p><p><strong>Methods: </strong>We integrated multiple publicly available databases, including TCGA, TISIDB, TISCH2, and UALCAN, to comprehensively investigate the role of NSUN7 in pan-cancer across various omics data types. The research included examining survival rates, genetic mutations, immune cell presence in tumors, analyzing differences in gene expression, and studying individual cells, among other things.</p><p><strong>Results: </strong>NSUN7 expression showed an increase across 12 cancer types and a decrease in another 12 types. NSUN7 was discovered to be linked with enhanced survival rates in bladder urothelial carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), pheochromocytoma and paraganglioma (PCPG), skin cutaneous melanoma (SKCM), and uveal melanoma (UVM).On the other hand, NSUN7 seemed to have a detrimental impact on the prognosis of glioblastoma multiforme/brain lower grade glioma (GBMLGG), adrenocortical carcinoma (ACC),acute myeloid leukemia (LAML), stomach adenocarcinoma (STAD), and brain lower grade glioma (LGG). Furthermore, our experimental validation confirmed the inhibitory effect of NSUN7 on proliferation of renal clear cell carcinoma while elucidating its specific part in blocking cell cycle progression.</p><p><strong>Conclusions: </strong>The findings underscore the potential utility of NSUN7 as a valuable prognostic indicator for patients and offer insights into the mechanisms underlying cancer initiation and progression.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"345"},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival.","authors":"Hung-Liang Pai, Wei-Ting Hsu, Chia-Chi Chang, Ming-Hsin Yeh","doi":"10.1007/s12672-025-02120-2","DOIUrl":"10.1007/s12672-025-02120-2","url":null,"abstract":"<p><p>Adenomyoepithelioma of the breast (AME) is a rare, biphasic tumor characterized by the coexistence of both epithelial and myoepithelial cell components, which can present as benign, atypical, or malignant forms. We present a 50-year-old female diagnosed with malignant AME (M-AME) exhibiting low-positive estrogen receptor (ER) expression of 5%, alongside pathogenic HRAS Q61R and PIK3CA H1047R mutations. Immunohistochemistry showed low-positive ER, negative progesterone receptor (PR), HER2, and a high Ki-67 index. Sanger sequencing identified HRAS and PIK3CA mutations. The tumor was staged as pT2N0M0 with no lymph node involvement. The patient underwent partial mastectomy, followed by sentinel lymph node biopsy, which showed no metastasis. Postoperatively, she received four cycles of adjuvant chemotherapy, followed by radiotherapy. The patient achieved disease-free survival at 10 months with no recurrence on imaging. This case highlights the challenges of ER classification in M-AME and highlights the significance of molecular profiling in guiding treatment. The concurrent HRAS and PIK3CA mutations suggest potential targeted therapies, emphasizing the importance of a multidisciplinary approach. Further research is needed to establish standardized treatment guidelines for M-AME.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"349"},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}